No Data
Ferment Launches $20M Studio Fund to Accelerate Biotech Solutions Across Vital Industries
Morgan Stanley Maintains Ginkgo Bioworks(DNA.US) With Hold Rating, Maintains Target Price $10
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Cuts Target Price to $6
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Maintains Target Price $10
Positive Outlook for Ginkgo Bioworks: Strategic Developments and Financial Strength Bolster Buy Rating